Medicenna Therapeutics (MDNA) Corporate presentation summary

Pipeline overview and technology platforms

• Three lead programs: MDNA11 (IL-2 superagonist), MDNA113 (PD-1 x IL-2 superkine), and Bizaxofusp (IL-4R targeted immunotoxin) with first- or best-in-class potential.

• Proprietary platforms include Superkine, BISKIT, and T-MASK for tunable cytokine engineering and targeted immunotherapy.

• Balanced pipeline spans early, mid, and late-stage assets, including preclinical autoimmune and inflammatory disease candidates.

Clinical program highlights

• MDNA11 shows 36% ORR as monotherapy and 43% ORR in combination with pembrolizumab in advanced solid tumors, including checkpoint inhibitor-resistant cancers.

• Durable disease control and deepening responses observed across multiple tumor types, with notable efficacy in melanoma, MSI-H, and TMB-H cancers.

• Bizaxofusp doubled median overall survival in recurrent glioblastoma (13.5 vs 7.2 months) and is phase 3 ready with orphan drug and fast track designations.

Differentiation and competitive positioning

• MDNA11 is a next-generation IL-2 superagonist with improved safety, PK, and efficacy over prior IL-2 therapies, targeting resistant and hard-to-treat tumors.

• MDNA113 is a conditionally activated, tumor-anchored anti-PD1 x IL-2 bifunctional molecule targeting IL-13Ra2, designed for high dosing and tumor specificity.

• Bizaxofusp acts as a molecular Trojan horse, bypassing the blood-brain barrier and disrupting the tumor microenvironment in brain cancers.